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Abstract
OBJECTIVE: To investigate effects of Saikosaponin
D (SSd) on syndecan-2, matrix metalloproteinases
(MMPs) and tissue inhibitor of metalloproteinas-
es-2 (TIMP-2) in livers of rat with hepatocellular car-
cinoma (HCC).
METHODS: Male SD rats were divided into control
(n=10), model (n=20) and SSd (n=20) groups, and
model and SSd groups given intragastric 0.2% (w/
v) N-diethylnitrosamine to induce HCC. SSd group
received 0.03% (w/v) SSd in saline. Liver samples
were analysed immunohistochemically for synde-
can-2, MMP-2, MMP-13 and TIMP-2 at 16 weeks.
RESULTS: The model group had more malignant
nodules than the SSd group; all model-group HCC
cells were grade III; SSd-group HCC cells were
grades I-II. Controls showed normal hepatic cell
phenotypes and no syndecan-2 + staining. Synde-
can-2 + staining was greater in the model group
(35.2%, P≤0.001) than in controls or the SSd group
(16.5% , P ≤ 0.001). The model group had more in-
tense MMP-2 + staining than controls (0.37 vs 0.27,
P≤0.01) or the SSd group (0.31 vs 0.37, P≤0.05); and
higher MMP-13+ staining (72.55%) than in controls
(12.55%, P≤0.001) and SSd group (20.18%, P≤0.01).
The model group also had more TIMP-2 + staining
(57.2% ) than controls (20.9% , P≤0.001) and SSd
group (22.7% , P≤0.001). Controls and SSd group
showed no difference in TIMP-2+ rates.
CONCLUSION: SSd inhibited HCC development,
and downregulated expression of syndecan-2,
MMP-2, MMP-13 and TIMP-2 in rat HCC liver tissue.
© 2012 JTCM. All rights reserved.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the seventh most
common cancer and the third leading cause of can-
cer-related deaths in the world, causing 500,000 deaths
annually, of which approximately half occur in China.1,2
The development of HCC is a multi-step process in-
cluding cellular adhesion and the destruction of extra-
cellular matrix (ECM). During this process, different
molecules in the ECM and receptors and/or ligands on
the surfaces of tumor cells play critical roles.
Syndecans (syndecan-1, -2, -3, and -4) are a family of
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heparan sulfate proteoglycans (HSPGs) contain a sin-
gle transmembrane core protein, with several heparan
sulfate (HS) and chondroitin sulfate (CS) side chains
attached. Previous studies have shown that syndecans
are involved in the development and metastasis of
HCC.3-7 Interestingly, different syndecan isoforms
seem to play distinct roles in carcinogenesis and inva-
sion. Syndecan-1expression in human HCC tissue is
negatively correlated with histologic dedifferentiation,
metastasis, and poor prognosis.3,5 However, syndecan-4
has been shown to induce human hepatoma growth by
activating the cell cycle and inhibiting tumor necrosis
factor alpha (TNF-α)-mediated apoptosis.7 Synde-
can-3 expression is also seen in HCC tissue, especially
in tumoral stromal vessels,6 suggesting it may play
some roles in tumoral angiogenesis.
The relationship between syndecan-2 and HCC is
largely unknown; only a recent cDNA microarray
study suggested that syndecan-2 gene expression in-
creases in HCC tissue.4 However, accumulating evi-
dence indicates that syndecan-2 affects other carcino-
ma occurrence and invasion such as pancreatic8 and
prostate cancers.9 It is unclear how syndecan-2 affects
cancer cell behavior, dedifferentiation and invasion.
However, considering that syndecans localizes on cell
surfaces, and its HS side chains can bind to a large vari-
ety of ligands in the ECM, including vascular endothe-
lial growth factor (VEGF), an important growth factor
involved in HCC10 angiogenesis and metastasis, it is
likely that syndecan-2 influences ligand-induced activa-
tion and signaling in cells, consequently inducing cell
migration11 and angiogenesis.12 Moreover, syndecans
bind to many structural ECM molecules such as colla-
gens I, III and V, fibronectin, thrombospondin and te-
nascin, which provide structural support for the cell–
ECM adhesion, and are already known to be involved
in HCC invasiveness and progression.13-16
Matrix metalloproteinases (MMPs) play critical roles in
carcinogenesis, including the destruction of ECM and
basement membranes.17 MMP expression positively
correlates with invasion and metastasis of HCC and
other malignant tumors.18,19 Interestingly, MMP-2,
MMP-9 and their major inhibitor, the tissue inhibitor
of matrix metalloproteinase inhibitor-2 (TIMP-2) ap-
parently influence HCC development and invasion, as
their higher expression in HCC tissues correlates more
closely to patient outcome than other MMPs and
TIMPs.20-22 The precise mechanism behind this correla-
tion is not very clear, although MMP-2 and MMP-9
are thought to affect ECM degradation, which facili-
tates invasion and metastasis of tumor cells.23 Besides
MMP-2 and MMP-9, MMP-13 is another ECM-deg-
radative enzyme associated with HCC.18 MMP-13 in-
fluences MMP cascades, both activating and being acti-
vated by several other MMPs such as MMP-2. More-
over, it has an exceptionally wide substrate specificity
compared to other MMPs24 and is capable of cleaving
native fibrillar collagens of types I, II, III, V and IX,
which are key molecules during liver fibrosis, a com-
mon phenomenon observed before and during the oc-
currence of HCC.
Saikosaponin D (SSd) is a major component of Chai
Hu (Bupleurum Falcatum), which is used to treat vari-
ous liver diseases in traditional Chinese medicine. This
triterpene saponin reportedly induces pleiotropic bio-
logical effects, such as anti-inflammatory and anti-con-
vulsive induction of differentiation, immuno-modula-
tory and antiproliferative activities. Our previous stud-
ies have shown that SSd significantly reduced hepato-
carcinogenesis,25 angiogenesis26 and liver fibrosis27 in ani-
mal models, indicating that SSd may inhibit the occur-
rence, development and metastasis of HCC through
multi-cascade effects. However, the mechanism details
are still largely unknown.
In this study, we investigated effects of SSd on the ex-
pression of syndecan-2 and MMP-2, MMP-13, and
TIMP-2 in liver tissue from a rat HCC model estab-
lished using N-diethylnitrosamine (DEN) treatment.
We found that SSd can inhibit the expression of these
molecules involving the occurrence, development and
metastasis of HCC.
METHODS
All chemicals were obtained from Xi'an Chemical Re-
agent Factory (Xi'an, China) unless otherwise stated,
and were of analytical grade or better.
Animal model preparation
The experiment was approved by the Animal Ethics
Committee, Medical School of Xi'an Jiaotong Universi-
ty (Xi'an, China). Use of animals in this study was in
accordance with the National Institute of Health publi-
cation 85-23 "Guide for Care and Use of Laboratory
Animals" (National Research Council, 1996).28 Fifty
male Sprague Dawley (SD) rats weighing (248 ± 12) g
(3-4 months old) were purchased from the Laboratory
Animal Center of the Medical School, Xi'an Jiaotong
University. Rats were acclimated for 7 days, then ran-
domly divided into 3 groups: controls (n=10), model
group (n=20) and SSd group (n=20). Rats in model
and SSd groups received 0.2% (w/v) DEN (Sigma-Al-
drich Co., St. Louis, MO, USA) in saline (10 ng of
DEN/g body weight/day) intragastrically every 5 days
for 16 weeks; 0.9% (w/v) normal saline was adminis-
tered to control rats. Simultaneously, 0.03% (w/v) SSd
in saline was administered daily to the SSd group by in-
traperitoneal injection at 1.5 mg/kg body weight. Dis-
tilled water was accessible freely to all rats.
Sample collection
The weights of the rats were measured every week. At
16 weeks after the initiation of experiment, all the rats
were scarified under general anesthesia. Hepatic tissues
were collected and fixed in 4% (w/v) paraformalde-
hyde in phosphate buffered saline (0.16M NaCl,
0.003M KCl, 0.008M Na2HPO4, 0.001M KH2PO4,
pH 7.3, PBS). The tissues were embedded in paraffin
and sectioned at 8-μm thickness.
Histological staining
After deparaffinization, sections were stained with he-
matoxylin and eosin (H&E) as usual. After dehydra-
tion sections were mounted using DPX mounting me-
dium (Thermo Fisher Scientific, Loughborough, UK).
Representative regions were photographed under
bright field optics using a Leica DMRB light micro-
scope (Leica, Wetzlar, Germany) equipped with digital
image acquisition.
Immunohistochemical staining
Immunohistochemical staining was performed using
the Mouse on Mouse™ (for syndecan-2, Vector labs, Pe-
terborough, UK) or Vectastain®, Elite® ABC Kits (for
MMP-2, MMP-13 & TIMP-2, Vector labs, Peterbor-
ough, UK) according to the manufacturers' protocols.
Briefly, sections were incubated with 0.3% (v/v) hydro-
gen peroxide for 30 min at room temperature to
quench endogenous peroxidase activity. After blocking
with mouse immunoglobulin (Ig) blocking reagent for
1 h or 2.5% (v/v) normal horse serum for 30 min at
room temperature, sections were incubated with rat an-
ti-syndecan-2 (Novus Biological, Cambridge, UK), rab-
bit anti-MMP-2 (Abcam, Cambridge, UK), goat an-
ti-MMP-13 (Santa Cruz Biotechnology, Ltd., Santa
Cruz, CA, USA) or rabbit anti-TIMP-2 (Abcam, Cam-
bridge, UK) primary antibody respectively for 60 min.
For the negative control, the primary antibody was re-
placed by PBS, 2 μg/mL rabbit IgG (DAKO, Cam-
bridge, UK) or 2 μg/mL goat IgG (DAKO, Cam-
bridge, UK). Sections were then incubated with biotin
labeled horse anti-rat, rabbit, or goat IgG for 30 min at
room temperature. After washing, sections were incu-
bated with Vectastain ABC reagent for 30 min. Sec-
tions were then visualised using Vector NovaRED™ kit
(Vector labs, Peterborough, UK) according to the man-
ufacturer's protocols. Cell nuclei were counterstained
with hematoxylin. After dehydration, sections were
mounted using DPX mountaining medium. Represen-
tative regions were then photographed under bright
field optics using a Leica DMRB bright field micro-
scope equipped with digital image acquisition.
Quantitative analysis for tissue staining rates
Positive staining in cells was quantitatively analyzed.
Sections of 4 liver tissues from 4 individual rats in each
experimental group were taken for analysis. For each
tissue, three sections were randomly selected, and posi-
tively and negatively stained cells in these sections were
counted using Image J software (National Institutes of
Health, Bethesda, MD, USA). The percentage of posi-
tive cells was then calculated as: [(positive stained cells)/
(positive stained cells+negative stained cells)]×100%.
Semi-quantitative analysis for the intensity of
MMP-2 positive staining in the tissue
Tissue MMP-2 + staining was analyzed by Integrated
Optical Density (IOD) using the Image-Pro Plus 5.1
software (Media Cybernetics, Inc., Bethesda, MD,
USA) as described previously29 with minor modifica-
tion. Briefly, four 40 × TIFF-format images from four
individual rats in each group was analyzed in a blinded
manner. All images were taken with the same micro-
scope and camera setting. The Image-pro Plus software
was used to calculate the average IOD per stained area
(μm2) (IOD/area) for MMP-2+ staining.
Statistical analyses
Data are presented as mean±S.E.M, with samples de-
rived from 4 animals in each group. Data were tested
for normality and equal variance. Student's t test or
one-way analysis of variance (ANOVA) plus Bonferro-
ni's post-test was carried out using GraphPad Prism
4.0 software (GraphPad Software Inc, La Jolla, CA,
USA). P≤0.05 was considered significant.
RESULTS
SSd reduced the number of malignant nodules and
hepatoma malignancy grade
Sixteen weeks after administering DEN, malignant
nodules were observed on surfaces of livers from rats in
model group, on average. The number of macroscopic
modules larger than 3 mm and 5 mm observed on the
surface of each liver tissues in the model group aver-
aged 33.4 and 4.9 respectively (the largest was approxi-
mately 1.5 cm × 1.0 cm × 0.8 cm); whereas in the SSD
group, the numbers of macroscopic nodules bigger
than 3 mm and 5 mm on single liver from SSd group
averaged significantly less—21.7 and 2.4, respectively
(Table 1, P≤0.01). H&E staining was used to identify
and classify the cancerous nodules pathologically ac-
cording to Edmondson.30 Hepatoma nodules in both
model and SSd groups were evident (Figure 1B & C).
However, the model group had more nodules than the
SSd group, similar with the macroscopic observation
described above. Hepatoma nodules in the model and
SSd groups were isolated by fibroblasts, which are be-
lieved to produce different collagen fibers to form fibro-
sis. Interestingly, the fibrosis observed in the model
group (Figure 1E) was evidently thicker than that in
the SSd group (Figure 1F). HCC cells dedifferentia-
tion was also investigated according to Edmondson.30
All cancer cells in the model group (Figure 1H) were
classified as grade III whereas the cells in SSd group
were evaluated as grade I– II (Figure 1I). There were
no macroscopic malignant nodules in the con-
trol-group livers, which showed normal morphology
and liver tissue structure (Figure 1A, D & G). This re-
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were collected and fixed in 4% (w/v) paraformalde-
hyde in phosphate buffered saline (0.16M NaCl,
0.003M KCl, 0.008M Na2HPO4, 0.001M KH2PO4,
pH 7.3, PBS). The tissues were embedded in paraffin
and sectioned at 8-μm thickness.
Histological staining
After deparaffinization, sections were stained with he-
matoxylin and eosin (H&E) as usual. After dehydra-
tion sections were mounted using DPX mounting me-
dium (Thermo Fisher Scientific, Loughborough, UK).
Representative regions were photographed under
bright field optics using a Leica DMRB light micro-
scope (Leica, Wetzlar, Germany) equipped with digital
image acquisition.
Immunohistochemical staining
Immunohistochemical staining was performed using
the Mouse on Mouse™ (for syndecan-2, Vector labs, Pe-
terborough, UK) or Vectastain®, Elite® ABC Kits (for
MMP-2, MMP-13 & TIMP-2, Vector labs, Peterbor-
ough, UK) according to the manufacturers' protocols.
Briefly, sections were incubated with 0.3% (v/v) hydro-
gen peroxide for 30 min at room temperature to
quench endogenous peroxidase activity. After blocking
with mouse immunoglobulin (Ig) blocking reagent for
1 h or 2.5% (v/v) normal horse serum for 30 min at
room temperature, sections were incubated with rat an-
ti-syndecan-2 (Novus Biological, Cambridge, UK), rab-
bit anti-MMP-2 (Abcam, Cambridge, UK), goat an-
ti-MMP-13 (Santa Cruz Biotechnology, Ltd., Santa
Cruz, CA, USA) or rabbit anti-TIMP-2 (Abcam, Cam-
bridge, UK) primary antibody respectively for 60 min.
For the negative control, the primary antibody was re-
placed by PBS, 2 μg/mL rabbit IgG (DAKO, Cam-
bridge, UK) or 2 μg/mL goat IgG (DAKO, Cam-
bridge, UK). Sections were then incubated with biotin
labeled horse anti-rat, rabbit, or goat IgG for 30 min at
room temperature. After washing, sections were incu-
bated with Vectastain ABC reagent for 30 min. Sec-
tions were then visualised using Vector NovaRED™ kit
(Vector labs, Peterborough, UK) according to the man-
ufacturer's protocols. Cell nuclei were counterstained
with hematoxylin. After dehydration, sections were
mounted using DPX mountaining medium. Represen-
tative regions were then photographed under bright
field optics using a Leica DMRB bright field micro-
scope equipped with digital image acquisition.
Quantitative analysis for tissue staining rates
Positive staining in cells was quantitatively analyzed.
Sections of 4 liver tissues from 4 individual rats in each
experimental group were taken for analysis. For each
tissue, three sections were randomly selected, and posi-
tively and negatively stained cells in these sections were
counted using Image J software (National Institutes of
Health, Bethesda, MD, USA). The percentage of posi-
tive cells was then calculated as: [(positive stained cells)/
(positive stained cells+negative stained cells)]×100%.
Semi-quantitative analysis for the intensity of
MMP-2 positive staining in the tissue
Tissue MMP-2 + staining was analyzed by Integrated
Optical Density (IOD) using the Image-Pro Plus 5.1
software (Media Cybernetics, Inc., Bethesda, MD,
USA) as described previously29 with minor modifica-
tion. Briefly, four 40 × TIFF-format images from four
individual rats in each group was analyzed in a blinded
manner. All images were taken with the same micro-
scope and camera setting. The Image-pro Plus software
was used to calculate the average IOD per stained area
(μm2) (IOD/area) for MMP-2+ staining.
Statistical analyses
Data are presented as mean±S.E.M, with samples de-
rived from 4 animals in each group. Data were tested
for normality and equal variance. Student's t test or
one-way analysis of variance (ANOVA) plus Bonferro-
ni's post-test was carried out using GraphPad Prism
4.0 software (GraphPad Software Inc, La Jolla, CA,
USA). P≤0.05 was considered significant.
RESULTS
SSd reduced the number of malignant nodules and
hepatoma malignancy grade
Sixteen weeks after administering DEN, malignant
nodules were observed on surfaces of livers from rats in
model group, on average. The number of macroscopic
modules larger than 3 mm and 5 mm observed on the
surface of each liver tissues in the model group aver-
aged 33.4 and 4.9 respectively (the largest was approxi-
mately 1.5 cm × 1.0 cm × 0.8 cm); whereas in the SSD
group, the numbers of macroscopic nodules bigger
than 3 mm and 5 mm on single liver from SSd group
averaged significantly less—21.7 and 2.4, respectively
(Table 1, P≤0.01). H&E staining was used to identify
and classify the cancerous nodules pathologically ac-
cording to Edmondson.30 Hepatoma nodules in both
model and SSd groups were evident (Figure 1B & C).
However, the model group had more nodules than the
SSd group, similar with the macroscopic observation
described above. Hepatoma nodules in the model and
SSd groups were isolated by fibroblasts, which are be-
lieved to produce different collagen fibers to form fibro-
sis. Interestingly, the fibrosis observed in the model
group (Figure 1E) was evidently thicker than that in
the SSd group (Figure 1F). HCC cells dedifferentia-
tion was also investigated according to Edmondson.30
All cancer cells in the model group (Figure 1H) were
classified as grade III whereas the cells in SSd group
were evaluated as grade I– II (Figure 1I). There were
no macroscopic malignant nodules in the con-
trol-group livers, which showed normal morphology
and liver tissue structure (Figure 1A, D & G). This re-
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sult indicated that SSd inhibits DEN-induced carcino-
genesis and cancer development in rats. To further ad-
dress its mechanism, we investigated the expression of
syndecan-2 in the liver tissues from these three groups.
Table 1 The number and size of malignant nodules in rat liv-
er tissue
Group
Control
group
Model
group
SSd
group
n
10
14
19
Nodules
≥3mm
0
33.4±7.9
21.7±5.1a
Nodules
≥5mm
0
4.9±1.9
2.4±1.3a
The biggest
nodule
(mm3)
0
122.8
39.6
Notes: aP≤0.01 when compared with model group.
SSd significantly decreased syndecan-2 expression in
HCC tissues
Syndecan-2 expression in liver tissue was investigated
using immunochemical staining. There was no appar-
ent syndecan-2+ staining in the liver tissue from control
group, either in portal area, central vein area or hepatic
lobule (Figure 2A&D). However, apparent syndecan-2+
liver tissue was seen in the model group, especially
around in the cytoplam of hepatoma cells in the cen-
tral vein (Figure 2B, black arrow—enlarged image is
shown in the small insert). Moreover, yndecan-2+ stain-
ing was also observed in the cytoplasm and/or cell
membranes in hepatoma cells far from portal area and
central vein (Figure 1-ii). Statistical analysis showed
much higher syndecan-2+ staining in the model group
(35.2%) than in the control group (no staining at all,
herein 0% ) (P≤0.001). In SSd group, syndecan-2 +
staining was still mainly seen in hepatoma cytoplasm
around portal area and central vein (Figure 2C). How-
ever, in hepatoma cells far from these areas, syndecan-2
staining was predominately seen on the cell mem-
branes instead of cytoplasm (Figure 2F). Syndecan-2 +
staining in SSd group was approximately 16.5%, signif-
icantly lower than in the model group (P≤0.001), but
higher than in the control group (P≤0.001). These re-
sults indicated that DEN-induced HCC in rat liver in-
creases syndecan-2 expression in cells, whereas SSd
treatment reduces syndecan-2 expression, suggesting a
correlation between HCC and syndecan-2 expression.
To further address the mechanism, we investigated en-
zymes that affect HCC development and metastasis,
such as MMP-2, MMP-13 and TIMP-2.
SSd significantly decreased MMP-2 expression in
HCC tissues
In controls, MMP-2+ staining was evenly distributed in
hepatocyte cytoplasm (Figure 3A&D), but was more
intensive in hepatoma cells, not only in cytoplasm but
also in some cell nuclei (Figure 3B&E). Interestingly,
MMP-2 staining in fibroblasts that form fibrosis
around hepatoma nodules and central vein was appar-
ently weaker than in hepatoma cells. In SSd-group tis-
sue, MMP-2+ staining was seen in some but not all hep-
atoma cytoplasm (Figure 3-III and iii). Unlike the
model group, MMP-2+ staining was also seen in fibro-
blasts forming fibrosis around hepatoma nodules (Fig-
ure 3C). Semi-quantitative analysis indicated higher
MMP-2 + staining intensity in model group than that
in controls (0.37 vs 0.27, P≤0.01). The SSd group
showed significantly reduced MMP-2 staining com-
pared to the model group (0.31 vs 0.37, P≤0.05), but
higher MMP-2 staining than in the control group
(0.31 vs 0.27, P≤0.05).
SSd significantly decreased MMP-13 expression in
HCC tissues
MMP-13 expression, which was also investigated using
immunohistochemical staining, was mainly distributed
on cell membranes in some but not all control-group
hepatocytes (Figure 4D). Noticeably, intensive
MMP-13 staining was observed in cytoplasm of 1-2
layers of cells around the central vein and portal area
(Figure 4A). In the model group, MMP-13 + staining
was observed in most of the hepatoma cytoplasm and
cell membranes, especially in cells around central vein
and portal area (Figure 4B&E). Statistical analysis
showed the model-group MMP-13 + staining rate
(72.55% ) to be higher than in the control group
(12.55%, P≤0.001). SSd-group MMP-13 staining was
mainly seen on cell membranes instead of cytoplasm in
hepatoma cells distant from central vein and portal ar-
ea (Figure 4E), similar to that observed in controls.
SSd-group MMP-13+ cells around central vein and por-
tal areas were dramatically fewer than in the model
group, almost similar to the control group (Figure 4-III).
The overall MMP-13 + rate in SSd group (20.18%) was
less than in the model group (72.55% , P≤0.01), but
higherthanforcontrols(12.55%,P≤0.05).
SSd significantly decreased TIMP-2 expression in
HCC tissues
In control samples, TIMP-2+ staining was seen in cells
around portal and central vein areas (Figure 5A), and
was also evident on cell membranes and in cytoplasm
in some cells in the hepatic plate (Figure 5D). The
overall TIMP-2 + rate in control-group hepatic cells
from was approximately 20.9%. In the DEN-induced
HCC model group, major TIMP-2 + staining was seen
in fibroblasts forming fibrosis around HCC nodules,
and cells in the portal and central vein areas (Figure
5B). TIMP-2+ staining was also seen in cytoplasm and
on cell membranes of some hepatoma cells (Figure
5E), and was much higher for model-group hepatoma
cells, at 57.2%, than t in the control group (P≤0.001).
TIMP-2 staining in the SSd group was similar to that
in the model group, mainly observed in the cells
around portal and central vein areas (Figure 5B),and in
fibroblasts forming fibrosis in liver tissue (Figure 5F),
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although it was much thinner than in model the
group. TIMP-2 + staining in some hepatoma cells was
similar to those in the control group, mainly localized
on cell membranes and cytoplasm (Figure 5F). The
SSd-group TIMP-2 + rate was significantly less than that
in the model group (P≤0.01). However, no difference
was observed between control and SSd groups (P>0.05).
DISCUSSION
Several rat models for liver carcinogenesis have been de-
scribed previously.31 However, unlike other models, the
DEN-induced HCC model reproduces the sequence of
cirrhosis and HCC, occurring as in human HCC devel-
opment.32 In this study, we used the DEN-induced rat
HCC model to mimic human HCC pathogenesis.
SSd, an herb used in traditional Chinese medicine to
treat liver disease, was administered to rats to address
its potential mechanism. The general condition of con-
trol rats was "normal" as expected. However, the
DEN-treated rats had apparent weight reduction, lags
in response, and decreased activity and diet intake, es-
A B C
D E F
G H I
Figure 1 H&E staining results for liver tissue from control (A,
D, G), model (B, E, H) and SSd groups (C, F, I)
Normal liver structure and cell morphology were observed
in the control group. However, apparent hepatoma nodules
and fibrosis in model group were evident when compared
with the control group. SSd reduced hepatoma nodule for-
mation and fibrosis compared with the model group. Hepa-
toma cells in model group were graded as III whereas those
in the SSd group were grade I-II according to Edmondson.
Scale bars: 400 µm (A–C); 100 µm (D–F); 50 µm (G–I).
A B C
D E F
Figure 2 Syndecan-2 immunohistochemical staining results
in rat liver tissues
Rats were treated with DEN with or without SSd for 16 weeks
to establish a hepatocellular carcinoma animal model. Liver
tissues were harvested and sectioned. Red: Syndecan-2 ex-
pression. Blue: cell nuclei, counterstained by hematoxylin.
A&D: control group; B&E: model group; C&F: SSd group.
Scale bars: 100 µm (A-C); 50 µm (A, E &F).
A B C
D E F
Figure 3 MMP-2 immunohistochemical staining results in rat
liver tissues
Rats were treated with DEN with or without SSd for 16
weeks to establish a hepatocellular carcinoma animal mod-
el. Liver tissues were harvested and sectioned. MMP-2 ex-
pression was stained by red color. Cell nucleuses were coun-
terstained by hematoxylin (blue color). A&D: control group;
B&E: model group; C&F: SSd group. Scale bar: 50 µm.
A B C
D E F
Figure 4 MMP-13 immunohistochemical staining in rat liver
tissues
Rats were treated with DEN with or without SSd for 16 weeks
to establish a hepatocellular carcinoma animal model. Liver
tissues were harvested and sectioned. Red: MMP-13 expres-
sion. Blue: cell nuclei, counterstained by hematoxylin. A&D:
control group; B&E: model group; C&F: SSd group. Scale bar:
100 µm (A-C); 50 µm (A,E&F).
A B C
D E F
Figure 5 TIMP-2 immunohistochemical staining results in rat
liver tissues
Rats were treated with DEN with or without SSd for 16 weeks
to establish a hepatocellular carcinoma animal model. Liver
tissues were harvested and sectioned. Red: TIMP-2 expres-
sion. Blue: cell nuclei, counterstained by hematoxylin. A&D:
control group; B&E: model group; C&F: SSd group. Scale
bars: 100 µm (A-C); 50 µm (A, E&F).
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pecially in the model group. By 16 weeks into this
study, six model-group rats had died (30% ) but only
one died in the SSd group (5%), indicating that SSd
could reduce mortality in rats with HCC. Moreover,
histological analysis indicated that SSd also decreased
hepatoma nodules and HCC malignancy. Although
these results suggest that SSd partially inhibits DEN-in-
duced HCC in a rat model, the mechanism is not clear.
Syndecan-2 is a multimeric cell-surface protein with
complex functions. The relationship between synde-
can-2 and carcinogenesis has been implied in in lung,
prostate, and colon cancers33,34 in which syndecan-2 ex-
pression was found to be elevated. However, synde-
can-2 expression in HCC has been little studied. In the
present study, we found no syndecan-2 expression in
control-group liver tissues. Surprisingly, intensive syn-
decan-2 staining was seen in liver tissue of rats with
DEN-induced HCC, especially in cells around the cen-
tral vein and portal areas, suggesting that syndecan-2
affects HCC occurrence, development and metastasis.
Although the precise mechanism is unclear, regulation
of tumor cell adhesion and migration, and facilitation
of angiogenesis may be involved. Reportedly, synde-
can-2 is required for lung carcinoma cell adhesion to fi-
bronectin; reduced syndecan-2 expression in those cells
decreases focal adhesion formation and migration.35
Moreover, overexpressed syndecan-2 in colon carcino-
mas increases cell proliferation, piling-up of cells in cul-
ture36,37 and invasive phenotypes.11 All these results sug-
gest that syndecan-2 overexpression on cell surfaces en-
hances carcinoma growth and migration through inter-
action with ECM components such as fibronectin—a
molecule also upregulated in HCC, especially on endo-
thelial blood vessel surfaces in cancerous tissue.38 Our
immunohistochemical results are consistent with this
premise, with no syndecan-2 expression in normal liver
tissue but significantly higher syndecan-2 staining in
DEN-induced HCC tissue, especially in the cells
around central vein and portal area, where are areas of
the liver that are both highly vulnerable to HCC metas-
tasis39 and that highly express fibronectin.40 Interesting-
ly, SSd significantly decreased DEN-induced synde-
can-2 expression in liver tissue, suggesting that SSd in-
hibits HCC by downregulating syndecan-2. Our earli-
er experiments showed that SSd could inhibit angio-
genesis in different animal models by down-regulating
expression of VEGF,26,27 a ligand that can bind to synde-
can-2 and thusinduce angiogenesis. Syndecan-2 down-
regulation reduces spreading and adhesion of endotheli-
al cells, and impairs formation of capillary-like struc-
tures, suggesting its necessity in angiogenesis.41 There-
fore, SSd may inhibit HCC angiogenesis by reducing
the expression of syndecan-2 and its VEGF binding.
Further studies are needed to address this mechanism.
MMPs are a family of extracellular endopeptidases that
selectively degrade ECM components and are thus
thought to contribute to tumor cell invasion. Several
studies showed that different MMPs, including
MMP-2,7,9, and13,play important roles inHCC.19,21,42-44
In this study, we found that the expression of MMP-2
and MMP-13 in DEN-induced HCC liver tissue were
much higher than in normal liver tissue, suggesting
that these two enzymes affect HCC occurrence and me-
tastasis, which is consistent with prior studies.18 Inter-
estingly, SSd treatment significantly reduced expression
of these enzymes in liver tissue, which correlates with
alleviation of HCC malignancy; this suggests that SSd
may prevent HCC invasion and metastasis by inhibit-
ing activities of MMP-2 and MMP-13. MMP-2 is a ge-
latinase, which degrades type IV collagen, the major
structural component of basement membranes. Unsur-
prisingly, HCC metastasis is apparently related to
MMP-2 expression, as basement membrane destruc-
tion is a key step in angiogenesis.45 MMP-13 is another
collagenase, widely expressed in many pathological con-
ditions. It is apparently central to the MMP cascade—
both activating and being activated by other MMPs
(MMP-14, -2 and -3)— and to collagen remodeling in
the angiogenic cascade.46 SSd may thus alleviate HCC
development and metastasis by inhibiting MMP-2 and
MMP-13 in tumoral angiogenesis.
MMP activity is specifically inhibited by the so-called
tissue inhibitors of metalloproteases (TIMPs). Current-
ly, four different TIMPs are known to exist:
TIMPs-1, -2, -3 and -4. TIMPs mediate ECM homeo-
stasis by regulating MMP activity, and may play impor-
tant roles in chronic liver disease.47 If TIMPs can inhib-
it MMPs in vivo, their expression might be expected to
be downregulated in HCC. However, TIMP-1 and/or
2 overexpression reportedly leads to increased hepato-
ma cell migration, and is associated with invasion and
metastases in HCC,48 and shortened overall survival of
HCC patients.18 Therefore, TIMP expression in HCC
is a likely marker for dynamic ECM remodeling,
which is dependent on the ratio between MMPs and
TIMPs. This premise is consistent with the correlation
between the MMP-2/TIMP-2 imbalance and metasta-
sis and prognosis in patients with HCC. Moreover, cir-
rhosis generally occurs in HCC,32 which is usually ac-
companied with a high expression of TIMP-2.49 In this
study, the most intensive TIMP-2 staining was seen in
fibroblasts instead of hepatoma cells, which differs
from the control group, and further illustrates the role
of TIMP-2 in HCC-associated cirrhosis. SSd reduced
TIMP-2 expression in liver tissue compared with that
in the model group, suggesting that SSd treatment
slows ECM remodeling and alleviates cirrhosis. This re-
sult also supports the view that MMPs and TIMPs do
more than degrade or build the ECM, and are multi-
functional proteins affecting cell behavior, cell– cell
communication and tumor angiogenesis.50
In summary, our data show elevated syndecan-2 expres-
sion in HCC tissue; SSd — which is used to treat
chronic liver disease in traditional Chinese medicine—
apparently counters HCC by reducing expression of
syndecan-2, MMP-2, MMP-13 and TIMP-2 in liver
tissue. Although the mechanism is unclear, SSd may in-
hibit carcinogenesis by reducing cell-ECM interaction,
thus slowing ECM remodeling and angiogenesis in
HCC. Whether syndecan-2 expression affects that of
MMP and TIMP-2 in HCC should be further investi-
gated, and may provide future therapeutic targets for
this common tumor.
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tissue. Although the mechanism is unclear, SSd may in-
hibit carcinogenesis by reducing cell-ECM interaction,
thus slowing ECM remodeling and angiogenesis in
HCC. Whether syndecan-2 expression affects that of
MMP and TIMP-2 in HCC should be further investi-
gated, and may provide future therapeutic targets for
this common tumor.
REFERENCES
1. Yang JD, Roberts LR. Hepatocellular carcinoma: A global
view. Nat Rev Gastroenterol Hepatol 2010; 7(8): 448-458.
2. Luk JM, Liu AM. Proteomics of hepatocellular carcinoma
in Chinese patients. Omics 2011; 15(5): 261-266.
3. Harada K, Masuda S, Hirano M, Nakanuma Y. Reduced
expression of syndecan-1 correlates with histologic dedif-
ferentiation, lymph node metastasis, and poor prognosis in
intrahepatic cholangiocarcinoma. Hum Pathol 2003; 34
(9): 857-863.
4. Liu Y, Zhu X, Zhu J, et al. Identification of differential ex-
pression of genes in hepatocellular carcinoma by suppres-
sion subtractive hybridization combined cDNA microar-
ray. Oncol Rep 2007; 18(4): 943-951.
5. Lu ZL, Zhang WM, Xiao G, et al. Study of expression of
CD138 and heparinase in hepatocellular carcinoma by tis-
sue microarray. Zhonghua Bing Li Xue Za Zhi 2006; 35
(2): 82-86.
6. Roskams T, De Vos R, David G, Van Damme B, Desmet
V. Heparan sulphate proteoglycan expression in human
primary liver tumours. J Pathol 1998; 185(3): 290-297.
7. Sutton A, Friand V, Brule-Donneger S, et al. Stromal
cell-derived factor-1/chemokine (C-X-C motif ) ligand 12
stimulates human hepatoma cell growth, migration, and
invasion. Mol Cancer Res 2007; 5(1): 21-33.
8. Hrabar D, Aralica G, Gomercic M, Ljubicic N, Kruslin
B, Tomas D. Epithelial and stromal expression of synde-
can-2 in pancreatic carcinoma. Anticancer Res 2010; 30
(7): 2749-2753.
9. Popovic A, Demirovic A, Spajic B, Stimac G, Kruslin B,
Tomas D. Expression and prognostic role of syndecan-2 in
prostate cancer. Prostate Cancer Prostatic Dis 2010; 13(1):
78-82.
10. Carey DJ. Syndecans: multifunctional cell-surface co-re-
ceptors. Biochem J 1997; 327 ( Pt 1): 1-16.
11. Contreras HR, Fabre M, Granes F, et al. Syndecan-2 ex-
pression in colorectal cancer-derived HT-29 M6 epithelial
cells induces a migratory phenotype. Biochem Biophys
Res Commun 2001; 286(4): 742-751.
12. Baston-Bust DM, Gotte M, Janni W, Krussel JS, Hess
AP. Syndecan-1 knock-down in decidualized human endo-
metrial stromal cells leads to significant changes in cyto-
kine and angiogenic factor expression patterns. Reprod Bi-
ol Endocrinol 2010; 8: 133.
13. Gupta N, Kakkar N, Vasishta RK. Pattern of fibronectin
in hepatocellular carcinoma and its significance. Indian J
Pathol Microbiol 2006; 49(3): 362-364.
14. Gulubova MV. Collagen type III and type IV detection in
and around human hepatocellular carcinoma. Gen Diagn
Pathol 1997; 142(3-4): 155-163.
15. Poon RT, Chung KK, Cheung ST, et al. Clinical signifi-
cance of thrombospondin 1 expression in hepatocellular
carcinoma. Clin Cancer Res 2004; 10(12 Pt 1): 4150-
4157.
16. Zhao M, Laissue JA, Zimmermann A. Tenascin and type
IV collagen expression in liver cell dysplasia and in hepato-
cellular carcinoma. Histol Histopathol 1996; 11(2):
323-333.
17. Egeblad M, Werb Z. New functions for the matrix metal-
loproteinases in cancer progression. Nat Rev Cancer 2002;
2(3): 161-174.
18. Altadill A, Rodriguez M, Gonzalez LO, et al. Liver expres-
sion of matrix metalloproteases and their inhibitors in he-
patocellular carcinoma. Dig Liver Dis 2009; 41(10):
740-748.
19. Gao ZH, Tretiakova MS, Liu WH, Gong C, Farris PD,
Hart J. Association of E-cadherin, matrix metalloproteinas-
es, and tissue inhibitors of metalloproteinases with the pro-
gression and metastasis of hepatocellular carcinoma. Mod
Pathol 2006; 19(4): 533-540.
20. Ogasawara S, Yano H, Momosaki S, et al. Expression of
matrix metalloproteinases (MMPs) in cultured hepatocellu-
lar carcinoma (HCC) cells and surgically resected HCC tis-
sues. Oncol Rep 2005; 13(6): 1043-1048.
21. Ishii Y, Nakasato Y, Kobayashi S, Yamazaki Y, Aoki T. A
study on angiogenesis-related matrix metalloproteinase net-
works in primary hepatocellular carcinoma. J Exp Clin
Cancer Res 2003; 22(3): 461-470.
22. Maatta M, Soini Y, Liakka A, Autio-Harmainen H. Differ-
ential expression of matrix metalloproteinase (MMP)-2,
MMP-9, and membrane type 1-MMP in hepatocellular
and pancreatic adenocarcinoma: implications for tumor
progression and clinical prognosis. Clin Cancer Res 2000;
6(7): 2726-2734.
23. Kessenbrock K, Plaks V, Werb Z. Matrix metalloprotein-
ases: regulators of the tumor microenvironment. Cell
2010; 141(1): 52-67.
24. Knauper V, Cowell S, Smith B, et al. The role of the
C-terminal domain of human collagenase-3 (MMP-13) in
the activation of procollagenase-3, substrate specificity,
and tissue inhibitor of metalloproteinase interaction. J Bi-
ol Chem 1997; 272(12): 7608-7616.
25. Liu Z, Chen H, Cheng Y, et al. Preventive effects of saiko-
saponin-d on experimental hepatocarcinogenesis in rats.
Journal of Xi'an Jiatong Unversity 2007; 28(6): 645-648.
26. Wang BF, Cheng YA, Dang SS. Angiogenesis inhibitory
effect of saikosaponin-d on chicken embryo. Zhongguo
Zhong Xi Yi Jie He Za Zhi 2009; 29(5): 425-429.
27. Dang SS, Wang BF, Cheng YA, Song P, Liu ZG, Li ZF. In-
hibitory effects of saikosaponin-d on CCl4-induced hepat-
ic fibrogenesis in rats. World J Gastroenterol 2007; 13(4):
557-563.
28. Clark JD, Gebhart GF, Gonder JC, Keeling ME, Kohn
DF. Special Report: The 1996 Guide for the Care and Use
of Laboratory Animals. Ilar J 1997; 38(1): 41-48.
29. Ivarsson K, Myllymaki L, Jansner K, Bruun A, Stenram
U, Tranberg KG. Heat shock protein 70 (HSP70) after la-
ser thermotherapy of an adenocarcinoma transplanted into
rat liver. Anticancer Res 2003; 23(5A): 3703-3712.
30. Edmondson HA, Steiner PE. Primary carcinoma of the
421
JTCM |www. journaltcm. com September 15, 2012 |volume 32 | Issue 3 |
Jia XL et al. Saikosaponin D on syndecan-2, MMPs and TIMP-2 in hepatocellular carcinoma
liver: a study of 100 cases among 48,900 necropsies. Can-
cer 1954; 7(3): 462-503.
31. Macejova D, Brtko J. Chemically induced carcinogenesis:
a comparison of 1-methyl-1-nitrosourea, 7,12-dimethyl-
benzanthracene,diethylnitroso-amine and azoxymethan
models (minireview). Endocr Regul 2001; 35(1): 53-59.
32. Schiffer E, Housset C, Cacheux W, et al. Gefitinib, an
EGFR inhibitor, prevents hepatocellular carcinoma devel-
opment in the rat liver with cirrhosis. Hepatology 2005; 41
(2): 307-314.
33. Gulyas M, Hjerpe A. Proteoglycans and WT1 as markers
for distinguishing adenocarcinoma, epithelioid mesothelio-
ma, and benign mesothelium. J Pathol 2003; 199(4):
479-487.
34. Ledezma R, Cifuentes F, Gallegos I, et al. Altered expres-
sion patterns of syndecan-1 and -2 predict biochemical re-
currence in prostate cancer. Asian J Androl 2011; 13(3):
476-480.
35. Munesue S, Kusano Y, Oguri K, et al. The role of synde-
can-2 in regulation of actin-cytoskeletal organization of
Lewis lung carcinoma-derived metastatic clones. Biochem
J 2002; 363(Pt 2): 201-209.
36. Park H, Kim Y, Lim Y, Han I, Oh ES. Syndecan-2 medi-
ates adhesion and proliferation of colon carcinoma cells. J
Biol Chem 2002; 277(33): 29730-29736.
37. Kim Y, Park H, Lim Y, et al. Decreased syndecan-2 expres-
sion correlates with trichostatin-A induced-morphological
changes and reduced tumorigenic activity in colon carcino-
ma cells. Oncogene 2003; 22(6): 826-830.
38. Tsumagari J. Fibronectin in human hepatocellular carci-
noma (HCC) and HCC cell lines. Acta Pathol Jpn 1987;
37(3): 413-423.
39. Dettmer M, Itin P, Miny P, Gandhi M, Cathomas G, Wil-
li N. Giant ectopic liver, hepatocellular carcinoma and
pachydermia-a rare genetic syndrome? Diagn Pathol 2011;
6: 75.
40. Geerts A, Geuze HJ, Slot JW, et al. Immunogold localiza-
tion of procollagen III, fibronectin and heparan sulfate
proteoglycan on ultrathin frozen sections of the normal rat
liver. Histochemistry 1986; 84(4-6): 355-362.
41. Noguer O, Villena J, Lorita J, Vilaro S, Reina M. Synde-
can-2 downregulation impairs angiogenesis in human mi-
crovascular endothelial cells. Exp Cell Res 2009; 315(5):
795-808.
42. Theret N, Musso O, Turlin B, et al. Increased extracellular
matrix remodeling is associated with tumor progression in
human hepatocellular carcinomas. Hepatology 2001; 34
(1): 82-88.
43. McKenna GJ, Chen Y, Smith RM, et al. A role for matrix
metalloproteinases and tumor host interaction in hepato-
cellular carcinomas. Am J Surg 2002; 183(5): 588-594.
44. Zhang Q, Chen X, Zhou J, et al. CD147, MMP-2,
MMP-9 and MVD-CD34 are significant predictors of re-
currence after liver transplantation in hepatocellular carci-
noma patients. Cancer Biol Ther 2006; 5(7): 808-814.
45. Bu W, Huang X, Tang Z. The role of MMP-2 in the inva-
sion and metastasis of hepatocellular carcinoma (HCC).
Zhonghua Yi Xue Za Zhi 1997; 77(9): 661-664.
46. Zijlstra A, Aimes RT, Zhu D, et al. Collagenolysis-depen-
dent angiogenesis mediated by matrix metalloprotein-
ase-13 (collagenase-3). J Biol Chem 2004; 279(26):
27633-27645.
47. Sawada S, Murakami K, Murata J, Tsukada K, Saiki I. Ac-
cumulation of extracellular matrix in the liver induces
high metastatic potential of hepatocellular carcinoma to
the lung. Int J Oncol 2001; 19(1): 65-70.
48. Roeb E, Bosserhoff AK, Hamacher S, et al. Enhanced mi-
gration of tissue inhibitor of metalloproteinase overexpress-
ing hepatoma cells is attributed to gelatinases: relevance to
intracellular signaling pathways. World J Gastroenterol
2005; 11(8): 1096-1104.
49. Hu YB, Li DG, Lu HM. Modified synthetic siRNA target-
ing tissue inhibitor of metalloproteinase-2 inhibits hepatic
fibrogenesis in rats. J Gene Med 2007; 9(3): 217-229.
50. McCawley LJ, Matrisian LM. Matrix metalloproteinases:
they're not just for matrix anymore! Curr Opin Cell Biol
2001; 13(5): 534-540.
422
